Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | EEF2K | O00418 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14936044 | 0.81 | GSR (0.46) | SLC6A9 | |
| SCHEMBL3702042 | 0.79 | GABBR2 (0.47) | FFAR1GABBR2GABBR1 | |
| SCHEMBL2701320 | 0.77 | CHRNB2 (0.50) | — | |
| SCHEMBL1670315 | 0.77 | FFAR1 (0.62) | FFAR1 | |
| SCHEMBL17311055 | 0.77 | SLC6A4 (0.37) | SLC6A9 | |
| Hydrochloric Acid SCHEMBL26134589 | 0.77 | SLC6A4 (0.40) | SLC6A9 | |
| SCHEMBL5640880 | 0.76 | PDPK1 (0.44) | PPARG | |
| SCHEMBL893601 | 0.76 | PDPK1 (0.44) | PPARG | |
| SCHEMBL5642476 | 0.76 | PDPK1 (0.44) | PPARG | |
| SCHEMBL4466281 | 0.76 | FFAR1 (0.53) | FFAR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | FFAR1 74/4885PPARG 542/4885GABBR2 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.